A Comprehensive Review of Antibiotic Resistance: Mechanisms, Causes, and Novel Therapeutic Approaches
DOI:
https://doi.org/10.22270/ajprd.v14i2.1739Abstract
Antibiotic resistance is a major global health concern that threatens the effective treatment of bacterial infections. The misuse and overuse of antibiotics in human medicine and agriculture have accelerated the emergence of resistant bacterial pathogens such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Various mechanisms, including genetic mutations and horizontal gene transfer, contribute to the spread of antimicrobial resistance. This review discusses the causes and mechanisms of antibiotic resistance as well as emerging strategies to combat it, including bacteriophage therapy, antimicrobial peptides, and advanced genomic technologies. Strengthening antimicrobial stewardship, improving surveillance systems, and developing new therapeutic approaches are essential to control the spread of antibiotic resistance and ensure effective treatment in the future.
Downloads
References
Velez R, Sloand E. Combating antibiotic resistance, mitigating future threats and ongoing initiatives. J. Clin. Nurs. 2016 Jul 1;25(13-14):1886-9.
Twisha Senjaliya, Muskan Patel, & Amar M. Raval. (2026). Strategies for Combating the Global Health Threat of Antibiotic Resistance: Novel Therapeutics and Combination Approaches. Asian Journal of Pharmaceutical Research and Development, 14(01), 122–130. https://doi.org/10.22270/ajprd.v14i01.1707
Akova M. Epidemiology of antimicrobial resistance in bloodstream infections. Virulence. 2016 Apr 2;7(3):252-66.
Mühlen S, Dersch P. Anti-virulence strategies to target bacterial infections. How to Overcome the Antibiotic Crisis: Facts, Challenges, Technologies and Future Perspectives. 2016 Mar 5:147-83.
Chellat MF, Raguž L, Riedl R. Targeting antibiotic resistance. Angewandte Chemie International Edition. 2016 Jun 1;55(23):6600-26.
Chellat, Mathieu F., Luka Raguž, and Rainer Riedl. "Targeting antibiotic resistance." Angewandte Chemie International Edition 55.23 (2016): 6600-6626.
Khameneh B, Diab R, Ghazvini K, Bazzaz BS. Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them. Microbial pathogenesis. 2016 Jun 1;95:32-42.
Wesgate R, Grasha P, Maillard JY. Use of a predictive protocol to measure the antimicrobial resistance risks associated with biocidal product usage. American journal of infection control. 2016 Apr 1;44(4):458-64.
Frieri M, Kumar K, Boutin A. Antibiotic resistance. Journal of infection and public health. 2017 Jul 1;10(4):369-78.
Plackett B. Why big pharma has abandoned antibiotics. Nature. 2020 Oct 22;586(7830):S50-.
Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, Foster S, Gilmore BF, Hancock RE, Harper D, Henderson IR. Alternatives to antibiotics—a pipeline portfolio review. The Lancet infectious diseases. 2016 Feb 1;16(2):239-51.
Anderson M, Cecchini M, Mossialos E, editors. Challenges to tackling antimicrobial resistance: economic and policy responses. Cambridge University Press; 2020 Apr 23.
Fortman JL, Mukhopadhyay A. The future of antibiotics: emerging technologies and stewardship. Trends in microbiology. 2016 Jul 1;24(7):515-7.
Matzov D, Bashan A, Yonath A. A bright future for antibiotics?. Annual review of biochemistry. 2017 Jun 20;86:567-83.
Weledji EP, Weledji EK, Assob JC, Nsagha DS. Pros, cons and future of antibiotics. New horizons in translational medicine. 2017 Nov 1;4(1-4):9-14.
Weledji EP, Weledji EK, Assob JC, Nsagha DS. Pros, cons and future of antibiotics. New horizons in translational medicine. 2017 Nov 1;4(1-4):9-14.
Hemmati F, Salehi R, Ghotaslou R, Samadi Kafil H, Hasani A, Gholizadeh P, Nouri R, Ahangarzadeh Rezaee M. Quorum quenching: A potential target for antipseudomonal therapy. Infection and Drug Resistance. 2020 Aug 24:2989-3005.
Golkar Z, Bagasra O, Pace DG. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. The Journal of Infection in Developing Countries. 2014 Feb 13;8(02):129-36.
Motley MP, Banerjee K, Fries BC. Monoclonal antibody-based therapies for bacterial infections. Current opinion in infectious diseases. 2019 Jun 1;32(3):210-6.
Spellberg B, Gilbert DN. The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett. Clinical infectious diseases. 2014 Sep 15;59(suppl_2):S71-5.
Bartlett JG, Gilbert DN, Spellberg B. Seven ways to preserve the miracle of antibiotics. Clinical infectious diseases. 2013 May 15;56(10):1445-50.
Christian KA, Ijaz K, Dowell SF, Chow CC, Chitale RA, Bresee JS, Mintz E, Pallansch MA, Wassilak S, McCray E, Arthur RR. What we are watching—five top global infectious disease threats, 2012: a perspective from CDC's Global Disease Detection Operations Center. Emerging health threats journal. 2013 Jan 1;6(1):20632.
Read AF, Woods RJ. Antibiotic resistance management. Evolution, medicine, and public health. 2014 Oct 28;2014(1):147.
Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharmacy and therapeutics. 2015 Apr;40(4):277.
Gross M. Antibiotics in crisis. Current biology. 2013 Dec 16;23(24):R1063-5.
Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, Laxminarayan R. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. The Lancet infectious diseases. 2014 Aug 1;14(8):742-50
Michael CA, Dominey-Howes D, Labbate M. The antimicrobial resistance crisis: causes, consequences, and management. Frontiers in public health. 2014 Sep 16;2:145.
Luyt CE, Bréchot N, Trouillet JL, Chastre J. Antibiotic stewardship in the intensive care unit. Critical care. 2014 Aug 13;18(5):480.
Lushniak BD. Surgeon general's perspectives. Public health reports. 2014 Mar;129(2):112.
Viswanathan VK. Off-label abuse of antibiotics by bacteria. Gut microbes. 2014 Jan 1;5(1):3-4..
Brooks GF, Butel JS, Morse SA. Jawetz, Melnick, & Adelberg's medical microbiology. (No Title). 2004 Mar.
Tortora GJ, Funke BR, Case CL, Weber D, Bair W. Microbiology: an introduction. Boston:: Pearson; 2013.
Kırmusaoğlu S. MRSA and MSSA: The mechanism of methicillin resistance and the influence of methicillin resistance on biofilm phenotype of Staphylococcus aureus. InThe rise of virulence and antibiotic resistance in Staphylococcus aureus 2017 Mar 8. IntechOpen.
Infectious Diseases Society of America (IDSA). Combating antimicrobial resistance: policy recommendations to save lives. Clinical Infectious Diseases. 2011 May 1;52(suppl_5):S397-428.
Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME. Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug?. Journal of Infection. 2013 May 1;66(5):401-14.
Bodi M, Ardanuy C, Rello J. Impact of Gram-positive resistance on outcome of nosocomial pneumonia. Critical care medicine. 2001 Apr 1;29(4):N82-6.
Perez F, Van Duin D. Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients. Cleveland Clinic journal of medicine. 2013 Apr;80(4):225.
Ena J, Dick RW, Jones RN, Wenzel RP. The epidemiology of intravenous vancomycin usage in a university hospital: a 10-year study. Jama. 1993 Feb 3;269(5):598-602.
Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, Reller LB. Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Annals of internal medicine. 2002 Nov 19;137(10):791-7.
Morin CA, Hadler JL. Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998. The Journal of infectious diseases. 2001 Oct 15;184(8):1029-34.
American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. American journal of respiratory and critical care medicine. 2005 Feb 15;171(4):388.
Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Annals of internal medicine. 2002 Jun 4;136(11):834-44.
van Duin D, Cober ED, Richter SS, Perez F, Cline M, Kaye KS, Kalayjian RC, Salata RA, Evans SR, Fowler Jr VG, Bonomo RA. Tigecycline therapy for carbapenem‐resistant K lebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance. Clinical Microbiology and Infection. 2014 Dec;20(12):O1117-20.
Kaye KS, Harris AD, Samore M, Carmeli Y. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infection Control & Hospital Epidemiology. 2005 Apr;26(4):346-51.
Harris AD, Carmeli Y, Samore MH, Kaye KS, Perencevich E. Impact of severity of illness bias and control group misclassification bias in case-control studies of antimicrobial-resistant organisms. Infection Control & Hospital Epidemiology. 2005 Apr;26(4):342-5.
McKinnell JA, Kunz DF, Chamot E, Patel M, Shirley RM, Moser SA, Baddley JW, Pappas PG, Miller LG. Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage. Infection Control & Hospital Epidemiology. 2012 Jul;33(7):718-24.
Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. science. 1999 May 21;284(5418):1318-22.
Ruimy R, Angebault C, Djossou F, Dupont C, Epelboin L, Jarraud S, Armand Lefevre L, Bes M, Elena Lixandru B, Bertine M, El Miniai A. Are host genetics the predominant determinant of persistent nasal Staphylococcus aureus carriage in humans?. The Journal of infectious diseases. 2010 Sep 15;202(6):924-34.
Woolhouse M, Farrar J. Policy: an intergovernmental panel on antimicrobial resistance. Nature. 2014 May 29;509(7502):555-7.
Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen JA, Klugman K, Davies S. Access to effective antimicrobials: a worldwide challenge. The Lancet. 2016 Jan 9;387(10014):168-75.
Lepape A, Monnet DL. Experience of European intensive care physicians with infections due to antibiotic-resistant bacteria, 2009. Eurosurveillance. 2009 Nov 12;14(45):19393.
US Department of Health and Human Services. Antibiotic resistance threats in the United States, 2019. (No Title). 2019.
Review on Antimicrobial Resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Review on Antimicrobial Resistance; 2014.
Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, Laxminarayan R. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. The Lancet infectious diseases. 2014 Aug 1;14(8):742-50.
World Health Organization. WHO Model Prescribing Information: drugs used in bacterial infections. World Health Organization; 2001.
Howard P, Pulcini C, Levy Hara G, West RM, Gould IM, Harbarth S, Nathwani D. An international cross-sectional survey of antimicrobial stewardship programmes in hospitals. Journal of Antimicrobial Chemotherapy. 2015 Apr;70(4):1245-55.
World Health Organization. Available online: https://www. who. int/news-room/fact-sheets/detail/obesity-and-overweight.
Singer AC, Shaw H, Rhodes V, Hart A. Review of antimicrobial resistance in the environment and its relevance to environmental regulators. Frontiers in microbiology. 2016 Nov 1;7:1728.
Nelson RE, Hyun D, Jezek A, Samore MH. Mortality, length of stay, and healthcare costs associated with multidrug-resistant bacterial infections among elderly hospitalized patients in the United States. Clinical Infectious Diseases. 2022 Mar 15;74(6):1070-80.
O'Neill J. Tackling drug-resistant infections globally: final report and recommendations.
Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, Han C, Bisignano C, Rao P, Wool E, Johnson SC. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The lancet. 2022 Feb 12;399(10325):629-55.
Jee Y, Carlson J, Rafai E, Musonda K, Huong TT, Daza P, Sattayawuthipong W, Yoon T. Antimicrobial resistance: a threat to global health. The Lancet Infectious Diseases. 2018 Sep 1;18(9):939-40
Ansari S, Hays JP, Kemp A, Okechukwu R, Murugaiyan J, Ekwanzala MD, Ruiz Alvarez MJ, Paul-Satyaseela M, Iwu CD, Balleste-Delpierre C, Septimus E. The potential impact of the COVID-19 pandemic on global antimicrobial and biocide resistance: an AMR Insights global perspective. JAC-antimicrobial resistance. 2021 Jun 1;3(2):dlab038.
Hay SI, Rao PC, Dolecek C, Day NP, Stergachis A, Lopez AD, Murray CJ. Measuring and mapping the global burden of antimicrobial resistance. BMC medicine. 2018 Jun 4;16(1):78.
Bengtsson B, Greko C. Antibiotic resistance—consequences for animal health, welfare, and food production. Upsala journal of medical sciences. 2014 May 1;119(2):96-102.
Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review. Frontiers in microbiology. 2019 Apr 1; 10:539.
Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clinical microbiology reviews. 2012 Jul;25(3):450-70.
Davis BD. Bactericidal synergism between β-lactams and aminoglycosides: mechanism and possible therapeutic implications. Reviews of infectious diseases. 1982 Mar 1:237-45.
Giamarellou H. Aminoglycosides plus beta-lactams against gram-negative organisms: Evaluation of in vitro synergy and chemical interactions. The American journal of medicine. 1986 Jun 30;80(6):126-37.
Yu L, Zhang J, Fu Y, Zhao Y, Wang Y, Zhao J, Guo Y, Li C, Zhang X. Synergetic effects of combined treatment of colistin with meropenem or amikacin on carbapenem-resistant Klebsiella pneumoniae in vitro. Frontiers in Cellular and Infection Microbiology. 2019 Dec 10;9:422.
Gunnison JB, Shevky MC, Bruff JA, Coleman VR, Jawetz E. Studies on antibiotic synergism and antagonism: the effect in vitro of combinations of antibiotics on bacteria of varying resistance to single antibiotics. Journal of Bacteriology. 1953 Aug;66(2):150-8.
Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R. Accelerated evolution of resistance in multidrug environments. Proceedings of the National Academy of Sciences. 2008 Sep 16;105(37):13977-81.
Papp-Wallace KM. The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections. Expert opinion on pharmacotherapy. 2019 Nov 22;20(17):2169-84.
Wenzler E, Deraedt MF, Harrington AT, Danizger LH. Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens. Diagnostic Microbiology and Infectious Disease. 2017 Aug 1;88(4):352-4.
Belley A, Barth P, Kashyap S, Lahlou O, Motta P, Knechtle P, Velicitat P. LB-4. Cefepime-Enmetazobactam Demonstrates Superiority to Piperacillin-Tazobactam in a Subgroup of Patients with Complicated Urinary Tract Infections/Acute Pyelonephritis Caused by Extended Spectrum β-Lactamase-Producing Enterobacterales. InOpen Forum Infectious Diseases 2020 Dec 31 (Vol. 7, No. Suppl 1, p. S845).
Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial antibiotic resistance: the most critical pathogens. Pathogens. 2021 Oct 12;10(10):1310.
Lenhard JR, Nation RL, Tsuji BT. Synergistic combinations of polymyxins. International journal of antimicrobial agents. 2016 Dec 1;48(6):607-13.
Brochado AR, Telzerow A, Bobonis J, Banzhaf M, Mateus A, Selkrig J, Huth E, Bassler S, Zamarreño Beas J, Zietek M, Ng N. Species-specific activity of antibacterial drug combinations. Nature. 2018 Jul 12;559(7713):259-63.
Pietsch F, Heidrich G, Nordholt N, Schreiber F. Prevalent synergy and antagonism among antibiotics and biocides in Pseudomonas aeruginosa. Frontiers in microbiology. 2021 Feb 4;11:615618.
World Health Organization. 2019 Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline. World Health Organization; 2020 Feb 20.
Pew Charitable Trusts.. Tracking the global pipeline of antibiotics in development, March 2021.
Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature reviews Drug discovery. 2007 Jan 1;6(1):29-40.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Prit Sunilbhai Patel, Amar M. Raval, Patel Annavi Ashish Kumar, Patel Poorv Dharmendra Kumar, Prajapati Tushar Ghanshyam, Patel Pankti bhavikkimar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
. 